Kruti Joshi
Employee at Janssen Scientific Affairs, LLC
Data updated
Papers
Trials
Research Footprint
Kruti Joshi appears in 7 tracked papers (2023–2025), most studied alongside Esketamine and Ketamine, across Depressive Disorders, Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).
Most-cited paper: Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance (12 citations).
Frequent co-authors: Maryia Zhdanava, Dominic Pilon and Aditi Shah.
Background & Research
Kruti Joshi is a researcher affiliated with Janssen Scientific Affairs in Titusville, New Jersey. Publicly indexed publications show her contributing to multiple studies on esketamine nasal spray, including access barriers, treatment patterns, costs, and productivity outcomes in treatment-resistant depression. The available evidence suggests she works in industry-led psychiatric health economics/real-world evidence rather than as an academic clinician.
Key Impact
Joshi appears to be a Janssen-affiliated researcher coauthoring multiple real-world evidence studies on esketamine access, barriers, utilization, and economic outcomes in treatment-resistant depression.
Collaboration Network
4 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Kruti Joshi is associated with.
Janssen Scientific Affairs, LLC
Janssen Research & Development
pharmaJanssen Research & Development is the pharmaceutical research and development arm of Johnson & Johnson (J&J). Operating under J&J's Innovative Medicine division, Janssen has sponsored clinical trials into ketamine-derived compounds, including esketamine (Spravato), the first FDA-approved psychedelic-adjacent treatment for treatment-resistant depression.
View stakeholder →